Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Work In Process: 2011-2018

Historic Work In Process for Anika Therapeutics (ANIK) over the last 7 years, with Sep 2018 value amounting to $5.9 million.

  • Anika Therapeutics' Work In Process fell 9.38% to $5.9 million in Q3 2018 from the same period last year, while for Sep 2018 it was $5.9 million, marking a year-over-year decrease of 9.38%. This contributed to the annual value of $6.1 million for FY2017, which is 9.05% up from last year.
  • Latest data reveals that Anika Therapeutics reported Work In Process of $5.9 million as of Q3 2018, which was down 5.92% from $6.3 million recorded in Q2 2018.
  • In the past 5 years, Anika Therapeutics' Work In Process ranged from a high of $6.6 million in Q3 2017 and a low of $2.2 million during Q2 2014.
  • For the 3-year period, Anika Therapeutics' Work In Process averaged around $6.0 million, with its median value being $5.9 million (2018).
  • Per our database at Business Quant, Anika Therapeutics' Work In Process surged by 94.43% in 2016 and then decreased by 9.38% in 2018.
  • Over the past 5 years, Anika Therapeutics' Work In Process (Quarterly) stood at $3.0 million in 2014, then spiked by 85.99% to $5.7 million in 2015, then declined by 1.71% to $5.6 million in 2016, then grew by 9.05% to $6.1 million in 2017, then declined by 9.38% to $5.9 million in 2018.
  • Its Work In Process stands at $5.9 million for Q3 2018, versus $6.3 million for Q2 2018 and $5.9 million for Q1 2018.